[AGM] Celltrion Healthcare sales to jump 70% this year: Seo

(Ref: The Korea Herald)
  • Celltrion chairman Seo Jung-jin said the company's Celltrion Healthcare unit expects sales to climb by more than 70 percent this year on strong biosimilar sales, The Korea Bizwire reported Friday.

  • "Conservatively speaking, I would say Celltrion Healthcare sales will reach between 1.6 trillion and 2 trillion won in sales," Seo remarked.

  • The projection comes as the drugmaker's three biosimilars Remsima, Truxima and Herzuma are gaining market share in Europe.

  • According to IMS Health data, Remsima controlled a 49-percent market share in Europe as of the end of September 2017, while Truxima, a biosimilar of Roche's Rituxan, is experiencing even faster growth.

  • Meanwhile, Seo said that Remsima will also post strong performance after the second quarter in the US, where it is sold by Pfizer under the name Inflectra.

  •  "It won't be difficult to gain additional market share in Europe, given that other biosimilars have insignificant presence," Seo noted.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>